In Pfizer Business Review, Established Products Unit Is Most "Complex," Simmons Says
This article was originally published in PharmAsia News
Executive Summary
With Pfizer Inc. in the midst of a strategic business review that includes an evaluation of all business units outside the "innovative core," even the company's Established Products business unit - made up of mature pharmaceuticals that have lost exclusivity in developed markets - could be spun out or put up for sale
You may also be interested in...
Sale Of Pfizer’s Established Products Not Off The Table, Exec Says
Pfizer CFO Frank D’Amelio talks about the big pharma’s long-term vision and cost-reduction initiatives during the Morgan Stanley Healthcare conference. Management will continue reviewing the portfolio on an ongoing basis to see how best to maximize shareholder value, he said.
Sale Of Pfizer’s Established Products Not Off The Table, Exec Says
Pfizer CFO Frank D’Amelio talks about the big pharma’s long-term vision and cost-reduction initiatives during the Morgan Stanley Healthcare conference. Management will continue reviewing the portfolio on an ongoing basis to see how best to maximize shareholder value, he said.
Reading Into Pfizer's Changes: First Steps For New CEO
Pfizer Inc.'s new CEO Ian Read came out of the gates strong during the company's year-end financial presentation Feb. 1, with news that investors greeted warmly: additional, unexpected cuts to R&D and further R&D reorganization, a $5 billion share buyback program, and assurance that all options are on the table when it comes to Pfizer's diversified portfolio of businesses.